Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes

References

• Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–873. doi:10.1016/j.jhep.2017.06.003
   PubMed Web of Science ®Google Scholar
• Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–867. doi:10.1038/ajg.2009.67
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218. doi:10.2337/dc06-2247
   PubMed Web of Science ®Google Scholar
• Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22:23–37. doi:10.1016/j.cld.2017.08.007
   PubMed Web of Science ®Google Scholar
• Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774. doi:10.1038/nature05315
   PubMed Web of Science ®Google Scholar
• Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92:131–155. doi:10.1152/physrev.00002.2011
   PubMed Web of Science ®Google Scholar
• Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97:1655–1662. doi:10.1210/jc.2011-2280
   PubMedGoogle Scholar
• Silswal N, Touchberry CD, Daniel DR, et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab. 2014;307:E426–436. doi:10.1152/ajpendo.00264.2014
   PubMed Web of Science ®Google Scholar
• Shi SY, Martin RG, Duncan RE, et al. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:10277–10288. doi:10.1074/jbc.M111.317453
   PubMedGoogle Scholar
• Xu L, Zhang L, Zhang H, et al. The participation of fibroblast growth factor 23 (FGF23) in the progression of osteoporosis via JAK/STAT pathway. J Cell Biochem. 2018;119:3819–3828. doi:10.1002/jcb.26332
   PubMedGoogle Scholar
• Mirza MA, Alsiö J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31:219–227. doi:10.1161/ATVBAHA.110.214619
   PubMed Web of Science ®Google Scholar
• He X, Shen Y, Ma X, et al. The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018;45:668–674. doi:10.1111/1440-1681.12933
   PubMedGoogle Scholar
• Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2016;45:765–781. doi:10.1016/j.ecl.2016.06.005
   PubMed Web of Science ®Google Scholar
• de Lédinghen V, Vergniol J, Foucher J, et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918. doi:10.1111/j.1478-3231.2012.02820.x
   PubMed Web of Science ®Google Scholar
• Kumar M, Rastogi A, Singh T, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol. 2013;28:1194–1201. doi:10.1111/jgh.12134
   PubMed Web of Science ®Google Scholar
• Chon YE, Jung KS, Kim SU, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102–109. doi:10.1111/liv.12282
   PubMed Web of Science ®Google Scholar
• Jian-Gao F; Chinese Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010;18:163–166.
   PubMedGoogle Scholar
• Cai YJ, Dong JJ, Wang XD, et al. A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B. J Viral Hepat. 2017;24:1005–1015. doi:10.1111/jvh.12715
   PubMedGoogle Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of Fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730. doi:10.1053/j.gastro.2019.01.042
   PubMed Web of Science ®Google Scholar
• Greco EA, Lenzi A, Migliaccio S. The obesity of bone. Ther Adv Endocrinol Metab. 2015;6:273–286. doi:10.1177/2042018815611004
   PubMed Web of Science ®Google Scholar
• Hu X, Ma X, Luo Y, et al. Associations of serum fibroblast growth factor 23 levels with obesity and visceral fat accumulation. Clin Nutr. 2018;37:223–228. doi:10.1016/j.clnu.2016.12.010
   PubMedGoogle Scholar
• Wijarnpreecha K, Thongprayoon C, Panjawatanan P, et al. Short sleep duration and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:1802–1807. doi:10.1111/jgh.13391
   PubMed Web of Science ®Google Scholar
• Peng K, Lin L, Wang Z, et al. Short sleep duration and longer daytime napping are associated with nonalcoholic fatty liver disease in chinese adults. J Diabetes. 2017;9:827–836. doi:10.1111/1753-0407.12489
   PubMedGoogle Scholar
• Marin-Alejandre BA, Abete I, Cantero I, et al. Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: a comparison with healthy controls. Nutrients. 2019;11:322. doi:10.3390/nu11020322
   PubMedGoogle Scholar
• Kim JH, Jung DH, Kwon YJ, et al. The impact of the sleep duration on NAFLD score in Korean middle-aged adults: a community-based cohort study. Sleep Med. 2019;57:144–150. doi:10.1016/j.sleep.2019.02.012
   PubMedGoogle Scholar
• Wasserman H, Ikomi C, Hafberg ET, et al. Two case reports of FGF23-induced hypophosphatemia in childhood biliary atresia. Pediatrics. 2016;138:e20154453. doi:10.1542/peds.2015-4453
   PubMedGoogle Scholar
• Masuda Y, Ohta H, Morita Y, et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol Pharm Bull. 2015;38:687–693. doi:10.1248/bpb.b14-00276
   PubMed Web of Science ®Google Scholar
• Mattinzoli D, Ikehata M, Tsugawa K, et al. FGF23 and fetuin-A interaction in the liver and in the circulation. Int J Biol Sci. 2018;14:586–598. doi:10.7150/ijbs.23256
   PubMedGoogle Scholar
• Fitzpatrick EA, Han X, Xiao Z, et al. Role of fibroblast growth factor-23 in innate immune responses. Front Endocrinol (Lausanne). 2018;9:320. doi:10.3389/fendo.2018.00320
   PubMed Web of Science ®Google Scholar
• Tarantino G, Costantini S, Citro V, et al. Interferon-alpha 2 but not Interferon-gamma serum levels are associated with intramuscular fat in obese patients with nonalcoholic fatty liver disease. J Transl Med. 2019;17:8. doi:10.1186/s12967-018-1754-6
   PubMedGoogle Scholar
• Wang X, Wei W, Krzeszinski JY, et al. A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 2015;22:811–824. doi:10.1016/j.cmet.2015.09.010
   PubMed Web of Science ®Google Scholar
• Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism. 2019;101:153994. doi:10.1016/j.metabol.2019.153994
   PubMed Web of Science ®Google Scholar